Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer

NCT01463891 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.

NCT NCT01463891
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01463891 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer
Lead sponsor
Eisai Co., Ltd.
Phase
Observational
Overall status
Completed
Start date
July 19, 2011
Completion date
November 27, 2013
Enrollment
963 (actual)
Sites
223

Conditions

As the registry lists them; a condition with its own page is linked.

inoperable or recurrent breast cancer